Search Follow us

Key contacts

Rachel Carroll

Rachel Carroll
President, Managing Partner

Maxim Jacobs

Maxim Jacobs
Managing Partner, North America

Regional office - North America
1185 Avenue of the Americas
3rd Floor, New York
NY 10036 United States

Tel: +1 646 653 7026
enquires@edisongroup.com

listed companies

Marriott Nordgold
Can-Fite BioPharma Sunesis Pharmaceuticals
Cleveland BioLabs MP Materials
Infinity Pharmaceuticals Exelixis
Idenix Pharmacyclics
Ariad Pharmaceuticals Arrowhead Research Corporation
AVEO Pharmaceuticals Sangamo BioSciences
TransDigm Group Array BioPharma
Alnylam Pharmaceuticals Spirit AeroSystems
FLIR Systems BioCryst Pharmaceuticals
See more

Companies with HQs in usa

Investment trusts Afferro Mining
Else Nutrition International Game Technology
Photocure AGBA
Seabridge Gold Caledonia Mining
Ion Beam Applications Veris Gold Corp
South American Silver Corp Ardea Biosciences
CAE Matamec Explorations
Woulfe Mining North Sea Energy
RGI International Carpathian Gold
Allot Communications Altius Minerals
See more

Latest research

AGBA

A transformational deal

Outlook | Technology | 26/04/2024

On 18 April, AGBA announced a surprise deal to acquire 100% of Triller Corp, a global AI-driven social video platform, in an all-stock transaction. Triller is privately-owned but has been independently valued at US$3.2bn. AGBA’s management is using a US$4bn valuation for the combined entity, in which AGBA shareholders will own 20% and Triller shareholders 80%. Triller recorded FY23 revenues of US$45m on 450m user accounts and 2.2m creators but is loss-making. In FY23, AGBA reported revenues…

Biodexa Pharmaceuticals

In a period of transition

Update | Pharmaceuticals & healthcare | 26/04/2024

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into…

Henderson Far East Income

Repositioning to raise total returns

Update | Investment trusts | 25/04/2024

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased…

International Public Partnerships

Consistently and responsibly delivering

Initiation | Investment trusts | 24/04/2024

International Public Partnerships’ (INPP’s) FY23 results show that it continues to deliver consistent and predictable returns for investors, while delivering environmental and social benefits for the individuals and communities that are served by its assets. Despite this strong performance and a substantial need for private infrastructure funding, the macroeconomic environment has weighed on INPP’s share price, in common with the wider sector. Regardless, attractive returns are…

Triple Point Energy Transition

Termination of coverage

Update | Investment trusts | 23/04/2024

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Edison North America

Edison’s North American office opened in 2011 to provide research services to companies listed on North American stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.